Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.67 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4100398 | 0.80 | EPHX2 (0.73) | ALDH1A1EPHX2MAPTHPGDSMN1; SMN2 | |
| SCHEMBL23005300 | 0.75 | CYP2C19 (0.62) | ALDH1A1EPHX2CYP2C19MAPTHPGD | |
| SCHEMBL16743659 | 0.74 | PPARA (0.46) | ALDH1A1EPHX2CYP2C19MAPTNPC1 | |
| SCHEMBL22441371 | 0.74 | MAPT (0.67) | ALDH1A1EPHX2CYP2C19MAPTHPGD | |
| SCHEMBL2650184 | 0.74 | MAPT (0.71) | ALDH1A1EPHX2CYP2C19MAPTHPGD | |
| SCHEMBL4609462 | 0.73 | EPHX2 (0.67) | ALDH1A1EPHX2MAPTHPGDMEN1 | |
| SCHEMBL694044 | 0.73 | MAPT (0.74) | ALDH1A1EPHX2CYP2C19MAPTHPGD | |
| SCHEMBL4610303 | 0.71 | PTGDR2 (0.51) | ALDH1A1EPHX2MAPTHPGDSMN1; SMN2 | |
| SCHEMBL4611011 | 0.71 | L3MBTL1 (0.51) | ALDH1A1EPHX2MAPTHPGDSMN1; SMN2 | |
| SCHEMBL9551946 | 0.70 | MAPT (0.70) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660437-B1 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | AMOREPACIFIC CORP (KR) | 2008-10-15 | — | — | EP | disclosed |
| CN-100351228-C | Hydroxamic acid derivatives and the method for preparing thereof | AMOREPACIFIC CORP (KR) | 2007-11-28 | — | — | CN | disclosed |
| US-7282522-B2 | Hydroxamic acid derivatives and the method for preparing thereof | AMOREPACIFIC CORPORATION (KR) | 2007-10-16 | — | — | US | disclosed |
| US-20060252834-A1 | Hydroxamic acid derivatives and the method for preparing thereof | AMOREPACIFIC CORPORATION (KR) | 2006-11-09 | — | — | US | disclosed |
| CN-1839115-A | Hydroxamic acid derivatives and preparation method thereof | AMOREPACIFIC CORP (KR) | 2006-09-27 | — | — | CN | disclosed |
| EP-1660437-A4 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | AMOREPACIFIC CORP (KR) | 2006-09-20 | — | — | EP | disclosed |
| EP-1660437-A1 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | Amorepacific Corporation (KR) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019162-A1 | HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF | AMOREPACIFIC CORPORATION (KR) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252834-A1 | Hydroxamic acid derivatives and the method for preparing thereof | HDAC7, SIRT7, HCAR1 | ALDH1A1 1218/4885EPHX2 1776/4885CYP2C19 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.